Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has work to do to win over patients and investors.
The post Sarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline appeared first on MedCity News.
